R ecent years have seen a dramatic increase in the use of chronic opioid therapy (COT) for chronic noncancer pain (CNCP). 1, 2 The risks and benefits of COT, and the issue of patient selection, have been areas of active research.
The selection of suitable candidates for COT has been considered the responsibility of the prescribing clinician. It involves identifying those patients with high likelihood of having good analgesia and functional improvement on opioid maintenance, and low risk for addiction, misuse, and nonadherence. 3 However, observational studies suggest that a large portion of patients (greater than a third for oral opioids) discontinue opioids within 6 months due to adverse effects or inadequate pain relief. 4 This suggests that self-selection plays an important role in determining who remains on COT. Thus, it is important to understand factors that influence patient desires to stop opioid therapy, beyond perceived adequacy of pain control and drug side effects. This inquiry should help us recognize and understand the patient's role in shared decision making concerning COT.
We investigated predictors of patient desire to stop or cut down opioids among COT recipients who consider opioid therapy helpful for pain relief. We use the term "ambivalence" to describe the conflicting attitudes toward opioid use expressed by those patients who find opioids helpful but also have the desire to discontinue or reduce opioids. We tested the hypothesis that ambivalence about opioids is more common among patients with clinically significant depressive symptoms. Although depression is associated with long-term opioid use, 5, 6 we expected depression to be associated with ambivalence about opioids because earlier research on medication adherence has found that depressed patients are more likely to express negative attitudes toward medication use, 7 and that they are less likely to adhere to prescribed medication regimens across a range of chronic conditions. [8] [9] [10] [11] [12] [13] A previous study based on the same survey of COT recipients as described in this study showed that depression is associated with patients experiencing more psychosocial difficulties that they specifically attribute to opioid use. 14 Thus, depression increases the likelihood that patients experience more psychosocial dysfunction related to opioid use and may make it more likely they want to stop or cut down opioids.
METHODS

Setting and Participants
Data described in this study were obtained as part of the CONsortium to Study Opioid Risks and Trends study, which surveyed adults of age 21 to 80 years receiving COT for CNCP. The participants were enrollees of Group Health Cooperative (GHC) of Washington State and Kaiser Permanente of Northern California (KPNC). The 2 health plans serve approximately a total of 4 million people.
Inclusion/Exclusion
To be eligible for the survey, health plan enrollees must have filled at least 10 opioid prescriptions or received at least 120 days supply in a 1-year period before the sample selection date, with at least 90 days between the first and last opioid dispensing in that year. Opioid usage was verified by GHC's and KPNC's electronic pharmacy databases where members obtain more than 90% of their prescription medications. Patients who had received a cancer diagnosis (except for nonmelanoma skin cancer) in local cancer registries or who had 2 or more cancer diagnoses in automated visit records in the year before sampling were excluded.
The sample for this study was restricted to patients who reported using opioids everyday in the last 2 weeks and rated their opioids as moderately, very, or extremely helpful. COT patients who did not find opioids helpful were excluded from our analyses to identify those who were ambivalent about opioid use among those who found opioids helpful in relieving their pain. Thus, 1737 patients were included and 426 patients were excluded.
Sampling
As most patients receiving COT receive <20 mg morphine equivalent dose (MED) per day, we used stratified sampling to select an equal number of survey respondents within 3 dosage strata (1 to 49 mg, 50 to 99 mg, and 100+ mg, MED). This way, patient subgroups using opioids at higher dosages were oversampled to ensure greater precision in data analysis. Observations were then weighted within dosage strata by the inverse probability of selection to obtain survey estimates representative of the population from which the sample was selected.
Telephone Survey
Telephone interviews were carried out between June to November 2008 at GHC, and from January to October 2009 at KPNC. A letter explaining the study was sent to potentially eligible patients. A 2 dollar bill was enclosed with the letter to potential GHC participants and a 5 dollar gift card for a national retail store to potential KPNC participants. Experienced survey interviewers working for the collaborating health plan research centers then called potential participants and asked them to participate in a 25 to 30-minute telephone interview, which was conducted using Computer-assisted Telephone Interview technology. Survey respondents were also asked to allow study staff to access their electronic healthcare date from the time they enrolled in the health plan until 3 years after the date of the interview. GHC participants who completed the interview received a $20 cash reimbursement and KNPC participants received a $50 gift card. The different incentive payments were based on the researchers' previous experience with achieving acceptable response rates at their respective institution. All study procedures were approved by the institutional review boards at both health plans.
Study Measures
Depression
The severity of depressive symptoms was measured using the 8-item version of the Patient Health Questionnaire (PHQ-8), a validated and widely used self-rated measure of depression. 15 On the basis of recommended cut points for PHQ-8, 15 scores below 5 were classified as nondepressed, 5 to 9 as mild depression, and 10+ as clinically significant depression.
Problems and Concerns Related to Opioid Use
Fourteen items from the survey were selected to measure recent problems and concerns patients attributed to opioid use (in the past 2 wk for common problems, in the past month or year for less common problems). 16 Psychosocial problems patients attributed to opioid use were measured with the following 8 items: loss of interest in usual activities; feeling slowed down, sluggish, or sedated; feeling depressed, down, or anxious; interference with work, family, or social responsibilities; difficulty thinking clearly; feeling sleepy or less alert when driving or doing something where alertness is needed; and bothersomeness of side effects. Opioid control concerns were assessed with the following 6 items: preoccupation with use of opioids; feeling unable to control use of opioids; needing a higher dose to get the same effect; worry about being dependent on or addicted to opioids; having opioid-related problems with family, friends, or coworkers; and patient report that family or friends perceived an opioid dependence or addiction problem.
Opioid Helpfulness
Patients were asked to rate, on a 5-point Likert scale, how helpful they found opioids were for relieving their pain in the past month. Possible ratings include "not at all," "a little," "moderately," "very," and "extremely" helpful.
Desire to Stop or Cut Down Opioid Use
Desire to stop opioids or cut down on the amount of opioid use was measured by patient agreement with the statement "In the past year I have wanted to stop using opiate pain medicines or to cut down on the amount of opiate medicines that I use." Responses were recorded on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree." Persons who strongly agreed or agreed with this item were classified as having the desire to stop or cut down. Those who strongly disagreed, disagreed, or were neutral were classified as not having the desire to stop or cut down.
Pain Intensity and Impact
Pain intensity was measured using a 0 to 10 pain intensity rating scale from the Graded Chronic Pain Scale 17 that rates average pain in the previous 3 months. A Pain Impact Scale 18,19 consisting of 11 yes-no items concerning effects of pain on daily activities in the past 2 weeks was also included.
Opioid Dosing
Average opioid daily dose and predominant opioid type (long-acting vs. short-acting) for the 90-day period before the survey were obtained using electronic pharmacy data. Average daily dose was estimated by the total MED divided by 90. Dose was converted to milligrams morphine equivalents according to previously described methods. 20 The predominant opioid type was defined as the type with the largest dispensed days supply during the time period.
Analyses SAS PROC SURVEYMEANS or PROC SURVEYREG software was used for the analyses to account for the stratified random sampling approach, providing estimates for the population surveyed. Basic statistics, including proportions, means, and standard deviations, were used to describe patients surveyed. Between-group differences in proportions were tested using w 2 statistics.
We examined the association between patient desire to stop or cut down opioid use and PHQ-8-depression score using logistic regression models to adjust for potential confounders. Covariates included patient characteristics (age, sex, body mass index, education), pain characteristics (mean days in pain in previous 6 months, average pain intensity, mean pain impact score), opioid use variables (average daily opioid dose, predominant use of long-acting vs. short-acting opioids), self-reported substance abuse problem (past and present), Charlson comorbidity score, 21 and health plan site. We also described differences in other patient problems and concerns with opioids between those who wanted to stop or cut down opioid use relative to those who did not. These descriptive analyses did not control for patient covariates.
RESULTS
Sample Characteristics
A total of 3790 patients were approached (2185 at GHC and 1605 at KPNC), of which 185 were ineligible (76 at GHC and 109 at KPNC). Two thousand one hundred sixtythree patients completed the interview (1191 at GHC and 972 at KPNC), for an overall response rate of 60% (57% at GHC and 65% at KPNC). The response rate difference between sites was presumably due to lower incentive payments at GHC. Response rates were higher for patients older than the age of 65 years in both health plans (65% at GHC and 68% at KPNC), but there were little sex differences in response rates. Response rates increased with average daily opioid dose at KPNC (58% for <50 mg MED, 66% for 50 to <100 mg MED, 71% for 100+ mg MED), but not at GHC (58%, 57%, 55%, respectively for the 3 dosage strata).
Among the 2163 survey respondents, analyses were restricted to those who reported having used opioids in the past 14 days and rated opioids as moderately, very, or extremely helpful, resulting in inclusion of 1737 (80%) patients in the analytic sample. As shown in Table 1 , the percentage of the patients in the sample who endorsed having wanted to stop or cut down their opioids was 43.3% (N = 795). Thus, among the patients who found opioids helpful in relieving their pain, nearly half said they would like to stop or reduce opioid usage.
Comparison Between Patients Who Had the Desire to Cut Down Opioid Use and Those Who Did Not
Patients reporting the desire to stop or cut down opioid use were, on average, younger than those who did not want to cut down ( Table 1 ). The 2 groups were similar in sex, body mass index, and education attainment. Patients with the desire to stop or cut down were also receiving higher average daily dose of opioids, whereas the 2 groups did not differ significantly in the predominant type of opioids they used, or the number of times per day they took opioids in the last 2 weeks. Both groups had an average >90 days' supply of opioids in the last 90 days according to automated pharmacy data, indicating that these patients were typically daily opioid users, consistent with their selfreport of daily opioid use in the previous 2 weeks.
The 2 groups were also similar in their average pain intensity and the number of days they had pain in the previous 6 months. However, the group wanting to stop or cut down opioids had higher mean Pain Impact scores. It is important to note that the 2 groups did not differ significantly in the percentage of patients perceiving opioids as very or extremely helpful versus only moderately helpful. There was also no significant difference between the 2 groups in Charlson comorbidity score or self-reported history of substance abuse problems.
Depression and the Desire to Cut Down Opioid Use
A significantly greater percentage of patients who reported the desire to stop or cut down opioid use had either mild (PHQ-8 scores 5 to 9) or clinically significant depression (PHQ-8 scores 10 or higher), compared with the group that did not endorse the desire to reduce opioid use. The group wanting to stop or cut down opioids also reported higher mean levels of depression symptoms ( Table 2 ). We further divided PHQ-8 symptoms into 2 domains: a Cognitive-Affective subscale ("Little interest or pleasure in doing things," "Feeling down, depressed, or hopeless," "Feeling bad about yourself," and "Trouble concentrating on things"), and a Somatic subscale ("Trouble falling or staying sleep, or sleeping too much," "Poor appetite or overeating," "Feeling tired or having little energy," and psychomotor changes). Table 2 shows that the group wanting to stop or cut down opioids scored higher in both domains than the comparison group.
We used logistic regression to estimate odds ratios for PHQ-8 score and other variables in predicting wanting to stop or cut down opioid use. Results are shown in Table 3 . Among the independent variables tested, greater depression severity (ie, higher PHQ-8 score) and younger age were associated with increased likelihood of wanting to stop or reduce opioid use.
Problems and Concerns Patients Attribute to Opioid Use
We compared the group that wanted to stop or cut down with those who did not on 14 items assessing problems and concerns that patients had regarding their opioid use. As shown in Table 4 , wanting to stop or cut down opioid use was associated reporting more psychosocial problems with opioid use and with having more opioid control concerns.
DISCUSSION
Among patients receiving COT and reporting it helpful in relieving their pain, nearly half expressed a desire to stop or cut down their opioid use. This conflicting attitude about opioid use was not associated with the degree of helpfulness opioids were perceived to have. Ambivalence was also not related to pain control, as average pain intensity ratings were identical in the 2 groups. Patients who desired to stop or cut down opioid use reported more psychosocial problems related to opioid use and had more concerns about controlling their use of opioids. They were also receiving higher opioid doses. Thus, even COT recipients who find opioids helpful for pain relief may be ambivalent about continuing on opioid therapy, especially among those who experience more psychosocial difficulty attributed to opioid use. This suggests that at least some patients receiving COT do recognize the problems with staying on opioids, and that they may be more open to discussions of opioid tapering or discontinuation than is generally assumed.
Of note, Pain Impact score, a measurement of effects of pain on daily activities, was correlated with the desire to stop or cut down opioid use in the analysis shown in Table 1 , but not in the analysis in Table 3 where depression indicator is included as a covariate. This difference can be accounted for by the fact that depression was correlated with high pain impact (data not shown). Similarly, the differential statistical significance in Tables 1 and  3 of opioid dose in its relation to the desire to stop or cut down opioid use can also be explained by the relationship between depression and high opioid doses (data not shown).
As hypothesized, we found that patient ambivalence was associated with depression. Depression is a robust predictor of poor adherence to drug regimens in other chronic conditions. 7 In the case of chronic pain and opioid therapy, there are a number of potential reasons for the link between depression and ambivalence about opioid use. First, opioids might have been used by patients as a de facto, but imperfect, treatment for depression. Depression has been associated with more pain complaints and higher pain severity. 22, 23 This may be why depressed patients are more likely to receive opioid therapy than their nondepressed counterparts. 5, 6 Although opioids might, in the short-term, be helpful in relieving depressive symptoms, 24 their longterm effect on mental health outcomes remains untested. Depression was found to be associated with reduced opioid analgesia in discogenic back pain. 25 Thus, depressed patients might seek relief of their painful symptoms through opioids, but then find this relief incomplete or inadequate, leading to ambivalence about using opioids. Second, depressive symptoms overlap with potential side effects of chronic opioid use, including sedation, decreased concentration and memory, and loss of interest in usual activities. Depressed patients might interpret their depressive symptoms as opioid side effects, leading to the desire to cut down. Third, due to the dual mechanism of higher baseline pain 22, 23 and decreased opioid analgesia, 25 depressed patients might be more likely to end up on higher doses of opioid medications. In fact, a previous report from the CONsortium to Study Opioid Risks and Trends study did find an association between depression and receiving higher doses of opioids for CNCP. 26 The same report also noted an association between younger age and higher opioid dose, which may help account for the significant link between younger age and the desire to cut down identified in the present study. Higher opioid dosing can potentially cause more bothersome side effects and opioid-related psychosocial difficulties that increase patient ambivalence about opioid use.
When depression symptom score was broken down into Cognitive-Affective and Somatic domains, patients who were ambivalent about their opioid use were found to have more severe cognitive and affective symptoms of depressions, and somatic symptoms, than those who were not ambivalent. This finding supports the possibility that patient expectation for pain relief and patient attribution of somatic symptoms may both play a part in whether or not they wish to discontinue opioids. Compared with nondepressed patients, those with depression may expect more pain relief from opioids but obtain less, and they experience more somatic symptoms which they may attribute more readily to the opioids. Thus, for clinicians initiating opioid therapy, an implication of the finding is that it is important to explore patient expectation about opioid efficacy and understand patient attribution styles as part of obtaining informed consent.
The study has a number of important limitations. Because of the cross-sectional survey design, this study cannot evaluate causal relationships among the variables of interest, including depression, opioid ambivalence, opioid dosing, and opioid difficulties. Mental disorders other than depression were not assessed in the survey. These disorders and substance use disorders are known to be associated with higher likelihood of receiving COT, 6, [27] [28] [29] [30] and therefore possibly play an important role in opioid ambivalence. The survey response rate was not optimal and differed between the 2 sites. Despite assurances of protection of confidentiality, some patients may have been concerned about providing information that they feel may jeopardize their access to pain medications. Pharmacy data on medications other than opioids was not collected; thus, it was not possible to control for certain potentially confounding variables such as antidepressant treatment.
The use of COT for CNCP is controversial, with significant uncertainty remaining about its long-term efficacy 31, 32 and potential harm including misuse and addiction. [33] [34] [35] Unintentional overdose from prescription opioids has become a leading cause of accidental death in multiple states, [36] [37] [38] drawing scrutiny regarding opioid dosing. 39 Our finding that a significant portion of patients receiving COT actually has the desire to decrease or stop their opioid medications suggests that it may often be possible to reach a mutual decision between the patient and the provider to taper or discontinue opioids when the risks and problems associated with opioid use outweigh the benefits.
In summary, among patients receiving COT for chronic pain who found opioids helpful, a large percentage (43.3%) thought about quitting or cutting down their opioid medications. Depression was linked to patient ambivalence about opioid use, as were patient-reported opioid-related psychosocial problems and opioid control concerns. These associations between depression and chronic opioid use, 5, 6 and between depression and opioid ambivalence presents a unique challenge to clinicians, especially those working in primary care settings, where the large majority of depressed and COT patients are treated. Depressed patients receiving COT often continue to have moderate-to-severe pain and unfavorable functional outcomes. In these patients, optimizing antidepressant therapy could be beneficial. 40 Furthermore, eliciting psychosocial problems that patients relate to opioid use, and opioid-related control concerns, may permit discussion of patient ambivalence about long-term use of opioid medications. For chronic pain patients not benefiting from COT, or who may be misusing prescription opioids, this may provide a basis for considering opioid discontinuation as an option. 
